Aktien Sensor

Biogen and City Therapeutics have formed a strategic partnership to develop innovative RNAi therapies, combining their expertise to create game-changing treatments for a wide range of diseases.

Biogen and City Therapeutics have formed a groundbreaking partnership to develop novel RNAi therapies for central nervous system diseases, leveraging cutting-edge technologies and expertise to potentially transform patient outcomes.

Biogen Inc’s stock price plummeted 4.93 US dollars in a single day, a victim of market volatility ahead of the Federal Reserve’s interest rate decision.

As of the latest data, Biogen’s stock price has closed at $119.12 USD, with a 52-week high of $238 USD and a current price-to-earnings ratio of 10.69.

Biogen’s stock has experienced a decline despite strong fourth-quarter earnings, but the company’s strategic initiatives and promising pipeline position it for long-term success.